<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="1745">
  <stage>Registered</stage>
  <submitdate>12/11/2007</submitdate>
  <approvaldate>12/11/2007</approvaldate>
  <nctid>NCT00557518</nctid>
  <trial_identification>
    <studytitle>Study of Alagebrium in Patients With Insulin-Dependent Type 1 Diabetes and Microalbuminuria</studytitle>
    <scientifictitle>A Randomized, Placebo-Controlled Trial of Alagebrium in Patients With Insulin-Dependent Type 1 Diabetes and Microalbuminuria</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>ALT-711-0424</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Diabetes Mellitus, Type 1</healthcondition>
    <healthcondition>Diabetic Nephropathy</healthcondition>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Diabetes</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Renal and Urogenital</conditioncode1>
      <conditioncode2>Kidney disease</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Alagebrium
Treatment: drugs - Placebo

Active Comparator: 1 - 

Placebo Comparator: 2 - 


Treatment: drugs: Alagebrium
200 mg bid

Treatment: drugs: Placebo
bid

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Change from baseline in albumin excretion rate (Âµg/min)</outcome>
      <timepoint>24 weeks</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Albumin:creatinine ratio(mg/g), plasma renin level, collagen markers, AGE related markers, 24 hour blood pressure determinations</outcome>
      <timepoint>24 weeks</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Insulin-dependent type 1 diabetes

          -  Age 18-65 years

          -  Diagnosis of established microalbuminuria

          -  Blood pressure &lt;140 mm Hg, diastolic blood pressure &lt;90 mm Hg

          -  HbA1c &lt;10%</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>65</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Body mass index &gt;40 kg/m2

          -  Cardiovascular event within 6 months prior to screening

          -  History of acute myocardial infarction within 12 months prior to screening

          -  Serum creatinine &gt;1.5 mg/dL

          -  Receiving chronic nonsteroidal anti-inflammatory therapy

          -  Receiving antihypertensive therapy except for angiotensin converting enzyme inhibitors
             or angiotensin receptor blockers

          -  Any significant systemic illnesses,medical conditions or abnormal laboratory values</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2>The people administering the treatment/s</masking2>
    <masking3>The people assessing the outcomes</masking3>
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>1/11/2007</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>80</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Terminated</recruitmentstatus>
    <anticipatedlastvisitdate>1/11/2009</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,VIC</recruitmentstate>
    <hospital>Royal Prince Alfred Hospital - Camperdown</hospital>
    <hospital>International Diabetes Institute - Caulfield</hospital>
    <hospital>Dept. of Clinical and Biomedical Science Myers House - Geelong</hospital>
    <hospital>Austin Health - Heidelburg</hospital>
    <hospital>The Alfred Hospital - Melbourne</hospital>
    <postcode>2050 - Camperdown</postcode>
    <postcode>3162 - Caulfield</postcode>
    <postcode>3220 - Geelong</postcode>
    <postcode>3084 - Heidelburg</postcode>
    <postcode>3004 - Melbourne</postcode>
    <countryoutsideaustralia>
      <country>Denmark</country>
      <state>Gentofte</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Synvista Therapeutics, Inc</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>Juvenile Diabetes Research Foundation</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Based upon the preclinical evidence in models of diabetic nephropathy under conditions
      approximating both type I and II diabetes, treatment with alagebrium appears to have
      favorable and advantageous effects on the biochemical, structural, pathological and
      functional hallmarks of diabetic nephropathy. The renoprotective effects of alagebrium in
      preclinical models favor the evaluation of this drug in patients with type I diabetes.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00557518</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Mark E Cooper, MBBS, PhD</name>
      <address>Baker Heart Research Institute, Melbourne, Australia</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>